Biotech

Bhavneesh Sharma

Top 20 Ranking (28.2% Avg Return) --TipRanks

Cymabay Therapeutics: An Options Strategy To Play The Upcoming Phase 2b Data For Seladelpar In NASH (End June)

Summary:

 

  • Cymabay (NASDAQ: CBAY) is developing PPAR-delta agonist, Seladelpar in treating non-alcoholic steatohepatitis, NASH.
  • Phase 2b data in this indication is expected towards the end of June this year and is expected to a price-moving binary event, with an expected move of approx. 35%.
  • In this brief note, I provide an options strategy to play this event that could return 30% in less than 4 weeks..

 

 

To read more, take a free trial of FAtrader.

Bhavneesh Sharma covers biotech as one of the original contributing analysts at FATRADER. A market expert with a medical degree and MBA, he is ranked among the top 15 financial bloggers and top 100 overall financial experts (including Wall Street analysts) on TipRanks.
Sign Up Now - Free 15-Day Trial! Go! Fatty!